Q32 Bio Inc (QTTB)
NASDAQ:QTTB
Want to see QTTB full AI Analyst Report?
QTTB Stock Chart & Stats
$5.85
-$0.23(-6.52%)
At close: 4:00 PM EST
$5.85
-$0.23(-6.52%)
Day’s Range― - ―
52-Week Range$1.35 - $13.19
Previous CloseN/A
Volume113.57K
Average Volume (3M)1.09M
Market Cap
$214.33M
Enterprise Value$101.42M
Total Cash (Recent Filing)$50.75M
Total Debt (Recent Filing)$10.99M
Price to Earnings (P/E)5.4
Beta0.52
Next Earnings
Aug 06, 2026EPS Estimate
-0.56Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.68
Shares Outstanding16,956,415
10 Day Avg. Volume2,665,592
30 Day Avg. Volume1,092,031
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.97
Price to Sales (P/S)0.76
P/FCF Ratio-1.22
Enterprise Value/Market Cap0.47
Enterprise Value/Revenue1.89
Enterprise Value/Gross Profit1.90
Enterprise Value/Ebitda4.58
Forecast
1Y Price Target
$14.25Price Target Upside143.59% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-1.83
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Improved ProfitabilityThe material step-up to strong TTM net and EBIT margins indicates the company has transitioned from prior losses toward profitable operations at current scale. Durable margins support reinvestment in R&D and reduce long-term dependence on dilutive financing if revenue stability persists.
Manageable Leverage And Capital BaseA materially lower debt-to-equity ratio and a meaningful equity and asset base improve solvency and financial flexibility. This reduces refinancing risk for multi-year clinical programs and supports negotiating partnerships or milestone financings without immediate balance-sheet strain.
Secured Institutional Financing And Expanded ATMA $55M private placement led by prominent healthcare investors and expanded ATM capacity materially extends runway to advance Phase 2 programs. Institutional backing and registration rights increase credibility and provide durable access to capital to fund clinical milestones rather than relying solely on ad hoc raises.
Bears Say
Persistent Negative Cash FlowSustained negative operating and free cash flow (~-$27.4M TTM) means the business is not yet self-funding. Over a 2-6 month horizon this heightens the structural need for capital to support trials and operations and increases execution risk if financing windows tighten.
Flat And Volatile Revenue GrowthFlat top-line in recent periods and historical volatility reduce confidence in the durability of current margins. Without clear, repeatable revenue streams or commercial products, profitability may rely on one-off events or milestone receipts, making long-term planning and scaling harder.
Ongoing Reliance On Equity FinancingRepeated use and expansion of ATM programs plus a large private placement signal structural reliance on external equity. This creates persistent dilution risk for shareholders and ties capital availability to market conditions, leaving programs exposed if financing terms worsen or investor interest wanes.
Q32 Bio News
QTTB FAQ
What was Q32 Bio Inc’s price range in the past 12 months?
Q32 Bio Inc lowest stock price was $1.34 and its highest was $13.19 in the past 12 months.
What is Q32 Bio Inc’s market cap?
Q32 Bio Inc’s market cap is $214.33M.
When is Q32 Bio Inc’s upcoming earnings report date?
Q32 Bio Inc’s upcoming earnings report date is Aug 06, 2026 which is in 63 days.
How were Q32 Bio Inc’s earnings last quarter?
Q32 Bio Inc released its earnings results on May 05, 2026. The company reported -$0.54 earnings per share for the quarter, beating the consensus estimate of -$0.68 by $0.14.
Is Q32 Bio Inc overvalued?
According to Wall Street analysts Q32 Bio Inc’s price is currently Undervalued.
Does Q32 Bio Inc pay dividends?
Q32 Bio Inc does not currently pay dividends.
What is Q32 Bio Inc’s EPS estimate?
Q32 Bio Inc’s EPS estimate is -0.56.
How many shares outstanding does Q32 Bio Inc have?
Q32 Bio Inc has 16,956,415 shares outstanding.
What happened to Q32 Bio Inc’s price movement after its last earnings report?
Q32 Bio Inc reported an EPS of -$0.54 in its last earnings report, beating expectations of -$0.68. Following the earnings report the stock price went up 1.984%.
Which hedge fund is a major shareholder of Q32 Bio Inc?
Currently, no hedge funds are holding shares in QTTB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Q32 Bio Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$14.25 (143.59% Upside)
$14.25 (143.59% Upside)
Blogger Sentiment
Bullish
QTTB Sentiment 70%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth $30.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 19.1%
Last 30 Days ▲ 26.7%
Last 30 Days ▲ 26.7%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
534.89%
12-Months-Change
Fundamentals
Return on Equity
230.68%
Trailing 12-Months
Asset Growth
-19.47%
Trailing 12-Months
Company Description
Q32 Bio Inc
Q32 Bio Inc., a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis. The company is also developing Bempikibart (ADX-914), a fully human antiinterleukin-7 receptor alpha antagonist monoclonal antibody designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin that is Phase II clinical trial for the treatment of atopic dermatitis and alopecia areata. Q32 Bio Inc. was formerly known as AdMIRx Inc. and changed its name to Q32 Bio Inc. in April 2020. The company was founded in 2017 and is based in Waltham, Massachusetts.
QTTB Stock 12 Month Forecast
Average Price Target
$14.25
▲(143.59% Upside)
Technical Analysis
Tempest Therapeutics
―
PDS Biotechnology
―
Grace Therapeutics
―
CalciMedica
―
Senti Biosciences
―
Ownership Overview
10.01% Insiders
2.71% Mutual Funds
48.01% Other Institutional Investors
36.56% Public Companies and Individual Investors
Options Prices
Currently, No data available
---